Can Alnylam Pharmaceuticals (ALNY) Stock Reach $400?

Key Takeaways

• Alnylam Pharmaceuticals, Inc. (ALNY) closed at $227.12 on August 13, 2026, making a move to $400 roughly a 76% gain from the latest close.
• The $400 level aligns closely with Wall Street's consensus 12-month price target and represents a recovery toward, not above, the stock's October 2025 high of $495.55.
• The strongest bullish factors are rapid Amvuttra-led revenue growth, a failed Phase 3 trial from a key competitor, and a still-constructive analyst consensus.
• The biggest obstacles are the July 2026 guidance cut, TTR franchise sales that missed expectations, emerging competition, and heavy technical overhead near $290 to $310.
• Key support sits near the 52-week low of $197.81; a credible push toward $400 would likely require first reclaiming the $300 psychological level.

Why Investors Are Watching the $400 Level

Alnylam Pharmaceuticals is a commercial-stage biopharmaceutical company that pioneered RNA interference, or RNAi, a mechanism used to silence disease-causing gene expression. The stock is not an ETF; it is a Nasdaq-listed common stock. ALNY traded as high as $495.55 in October 2025, so $400 is not a new record. It is a round-number recovery target that sits near the average analyst price target and therefore appears frequently in investor searches and market commentary.

Current Market Position

As of the August 13, 2026 close, ALNY traded at $227.12, up 1.42% on the day, with pre-market quotes on August 14 indicating a modest continuation near $228 to $230. The stock has a market capitalization near $30.4 billion and a trailing price-to-earnings ratio near 39. Its 52-week range is $197.81 to $495.55, meaning shares are roughly 54% below their high and about 15% above their low.

The sharp decline from the high reflects a July 2026 reset. After second-quarter results, management trimmed 2026 guidance, and total TTR franchise sales of about $1.03 billion for the quarter came in below expectations. Shares fell to the 52-week low of $197.81 on July 30 before staging a partial rebound.

What Could Drive the Next Leg Higher

• Amvuttra momentum: Alnylam's lead product, Amvuttra, is approved for transthyretin amyloidosis with cardiomyopathy and polyneuropathy. First-quarter 2026 revenue reached $1.17 billion, up 96.4% year over year, showing that underlying product demand remains strong even as near-term guidance disappointed.
• Competitive relief: In July, Ionis Pharmaceuticals reported a failed Phase 3 trial in ATTR-CM. Analysts viewed that setback as reducing a key rival to Alnylam's TTR franchise, improving the company's pricing and market-share outlook.
• Analyst support: The consensus rating is Moderate Buy, with an average 12-month target near $400. Raymond James upgraded the stock to Strong Buy with a $420 target in early August, while other bullish targets remain in the $420 to $485 range.
• Longer-term pipeline: Alnylam is developing next-generation RNAi therapies, including nucresiran, which offers deeper knockdown and less frequent dosing. That program could extend the TTR franchise into the next decade.

What Could Prevent the Move

• Execution concerns: The July guidance cut and the TTR sales miss show that even high-growth franchises can disappoint against elevated expectations. Another quarter of slower Amvuttra uptake would pressure the stock price target debate.
• Competition: Ionis Pharmaceuticals and AstraZeneca market Wainua in ATTR-PN, and generic competition for tafamidis could emerge as early as late 2028, potentially reshaping the ATTR-CM treatment landscape.
• Valuation: At $400, ALNY would be valued near $53 billion. Based on the 2027 consensus earnings estimate near $9.88, that is roughly 40 times forward earnings, a multiple that leaves little room for operational missteps.
• Technical overhead: The 50-day moving average near $290 and the 200-day moving average near $310 represent a supply zone where sellers have repeatedly emerged.

Technical Levels That Matter

Support is strongest near the July 2026 low of $197.81, reinforced by the psychological $200 level. On the upside, ALNY must first clear the $250 area, then the $290 to $310 zone containing the 50-day and 200-day moving averages. A decisive break and hold above that zone would be an important structural signal, opening a path toward $350 and then the $400 round-number resistance. Until then, the longer-term trend remains corrective despite the recent rebound.

AI Daily Buy/Sell Signals

Tickeron's AI Daily Buy/Sell Signals provide traders with a data-driven way to monitor names like Alnylam alongside thousands of other stocks and ETFs. The system uses artificial intelligence to continuously scan changing market conditions, technical behavior, and AI-driven analysis, then generates Buy, Sell, or Hold signals. This allows traders to discover new opportunities, track existing positions, and recognize shifting trends more efficiently than manual screening. For investors following ALNY's progress toward higher price levels, such tools can help identify when momentum is strengthening or fading. Consider exploring the signals to support a more disciplined, systematic approach to market monitoring.

Final Assessment

A move to $400 appears ambitious from $227.12, but it is not unrealistic for a stock that traded near $495 less than a year ago. The route would likely require renewed confidence in Amvuttra growth, clear evidence that the 2026 guidance reset is complete, and a technical recovery back above the $290 to $310 zone. The failed Ionis trial and broadly positive analyst targets support the bullish case, while the guidance cut, competition, and rich valuation are the principal counterweights. Investors should monitor quarterly TTR sales, the nucresiran pipeline, and whether ALNY can hold above $200 and ultimately reclaim $300 before the $400 conversation becomes actionable.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.